The effect of crocetin supplementation on markers of atherogenic risk in patients with coronary artery disease: a pilot, randomized, double-blind, placebo-controlled clinical trial.
Saeed AbedimaneshS Zahra BathaieOstadrahimi AlirezaMohammad Asghari JafarabadiMohammadreza Taban-SadeghiPublished in: Food & function (2019)
As the first human study, we showed the ability of crocetin to alter the expression of atherogenic genes and endothelial cell adhesion molecules in CAD patients. It appears that crocetin could be considered as a promising anti-atherogenic candidate for future studies.
Keyphrases
- double blind
- placebo controlled
- clinical trial
- cell adhesion
- endothelial cells
- end stage renal disease
- phase ii
- study protocol
- ejection fraction
- phase iii
- poor prognosis
- coronary artery disease
- prognostic factors
- open label
- peritoneal dialysis
- genome wide
- squamous cell carcinoma
- gene expression
- current status
- patient reported outcomes
- binding protein
- patient reported
- pluripotent stem cells
- rectal cancer
- locally advanced